Janus Kinase Inhibitor Market – Size, Share,
Outlook, and Opportunity Analysis, 2018 –
2026
Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in
cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and
ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT
(Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the
transcription of genes which are critical for signal cascade involved in inflammatory and
immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune
disorders such as rheumatoid arthritis.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2553
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in
immune response signaling. For instance, in June 2018, Eli Lilly and Company announced
approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an
oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in
combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs)
or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases
the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore,
increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market
growth over the forecast period.
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation
of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic
disease, which is characterized by inflammation of connective tissues such as cartilage and
blood vessel lining. According to National Center for Biotechnology Information (NCBI), the
highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000